Long-term data from the CHRYSALIS trial (NCT02609776) continued to demonstrate the clinical benefit of amivantamabvmjw (Rybrevant), according to study results presented at the European Lung Cancer...
New analysis provides insight into molecular mechanisms that can lead to disease in people lung cancer Infection with SARS-CoV-2 increases risk of severe disease According to...
In the Phase 1/2 KRYSTAL-1 trial (NCT03785249), the single agent adagressive provided promising objective response and disease control rate (DCR), and overall survival (OS) in previously...
However, only a small proportion of Americans who meet the criteria set by the USPSTF guidelines are screened. Estimates of percentages vary, but range from 6%...
Cancer mortality has declined in the United States for the second consecutive year. This is mainly due to the reduced incidence and mortality of cancer. Non-small...
The efficacy and safety of atezolizumab as first-line therapy for advanced NSCLC with high levels of PD-L1 expression are unclear and require additional treatment options, the...
Recent Comments